Analyst Consensus ?
ConsensusBuy36 ratings
Bullish2672.2%
Neutral1027.8%
Bearish00.0%
FN2 Earnings Intelligence
Charles River Laboratories International, Inc. analyst ratings
Charles River Laboratories International, Inc. (CRL) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$376.1Current
$151Low
$302.11Average
$465High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 13, 2026 |
| Jefferies | Buy | Buy | Maintain | Sep 28, 2026 |
| TD Cowen | Buy | Buy | Maintain | Sep 25, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Sep 25, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Sep 25, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 25, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Sep 25, 2026 |
| Barclays | Overweight | Overweight | Maintain | Sep 25, 2026 |
| Baird | Outperform | Outperform | Maintain | Sep 25, 2026 |
| JP Morgan | Overweight | Neutral | Upgrade | Aug 6, 2026 |
| CLSA | Hold | Outperform | Downgrade | Jul 20, 2026 |
| UBS | Neutral | Neutral | Maintain | Feb 25, 2026 |
| Citigroup | Buy | Buy | Maintain | Jan 16, 2026 |
| William Blair | Outperform | Market Perform | Upgrade | Oct 6, 2025 |
| Redburn Atlantic | Buy | Neutral | Upgrade | May 23, 2025 |
| Goldman Sachs | Neutral | Buy | Downgrade | Mar 21, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Dec 13, 2024 |
| Argus Research | Hold | Buy | Downgrade | Jun 28, 2024 |
| Guggenheim | Neutral | Buy | Downgrade | Feb 15, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Sep 22, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | May 12, 2023 |
| Keybanc | Overweight | Overweight | Maintain | May 5, 2022 |
| Stephens & Co. | Overweight | Overweight | Maintain | Apr 7, 2022 |
| Truist Securities | Buy | Buy | Maintain | May 25, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 8, 2020 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Feb 18, 2020 |
| CFRA | Strong Buy | Strong Buy | Maintain | Feb 11, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Oct 18, 2019 |
| Raymond James | Outperform | Outperform | Maintain | Nov 8, 2018 |
| Argus | Buy | Buy | Maintain | Aug 27, 2018 |
| Mitsubishi UFJ | Neutral | Neutral | Maintain | Apr 20, 2018 |
| Gabelli & Co. | Buy | Buy | Maintain | Apr 26, 2016 |
| Edward Jones | Buy | Neutral | Upgrade | May 4, 2015 |
| Cantor Fitzgerald | Buy | Buy | Maintain | Oct 1, 2013 |
| Sterne Agee | Buy | Buy | Maintain | Jun 11, 2013 |
| ISI Group | Neutral | Neutral | Maintain | Feb 20, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $376.1. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $340 | $301.14 | -9.6% | Oct 12, 2026 |
| UBS | Kevin Caliendo | $357 | $295.96 | -5.1% | Sep 30, 2026 |
| Jefferies | David Windley | $340 | $292.84 | -9.6% | Sep 28, 2026 |
| Deutsche Bank | Justin Bowers | $320 | $291.16 | -14.9% | Sep 25, 2026 |
| RBC Capital | Analyst unavailable | $322 | $291.11 | -14.4% | Sep 25, 2026 |
| Evercore ISI | Analyst unavailable | $330 | $294.44 | -12.3% | Sep 25, 2026 |
| Robert W. Baird | Analyst unavailable | $334 | $294.44 | -11.2% | Sep 25, 2026 |
| Mizuho Securities | Ann Hynes | $295 | $294.44 | -21.6% | Sep 25, 2026 |
| Barclays | Analyst unavailable | $330 | $294.44 | -12.3% | Sep 25, 2026 |
| Argus Research | Analyst unavailable | $330 | $279.4 | -12.3% | Sep 17, 2026 |
| Evercore ISI | Analyst unavailable | $320 | $277.18 | -14.9% | Sep 11, 2026 |
| Piper Sandler | Analyst unavailable | $300 | $269.64 | -20.2% | Aug 10, 2026 |
| Mizuho Securities | Analyst unavailable | $264 | $267.49 | -29.8% | Aug 10, 2026 |
| Morgan Stanley | Analyst unavailable | $300 | $264.05 | -20.2% | Aug 7, 2026 |
| Robert W. Baird | Analyst unavailable | $291 | $258.92 | -22.6% | Aug 6, 2026 |
| RBC Capital | Analyst unavailable | $282 | $260.72 | -25.0% | Aug 6, 2026 |
| Barclays | Analyst unavailable | $300 | $260.72 | -20.2% | Aug 5, 2026 |
| Mizuho Securities | Analyst unavailable | $230 | $233.41 | -38.8% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $260 | $223.96 | -30.9% | Jul 9, 2026 |
| Bernstein | Analyst unavailable | $250 | $226.79 | -33.5% | Jul 1, 2026 |
| Morgan Stanley | Analyst unavailable | $220 | $184.79 | -41.5% | Jun 17, 2026 |
| CLSA | Analyst unavailable | $219 | $181.34 | -41.8% | May 29, 2026 |
| Robert W. Baird | Eric Coldwell | $213 | $175.56 | -43.4% | May 8, 2026 |
| Evercore ISI | Analyst unavailable | $220 | $176.32 | -41.5% | May 8, 2026 |
| Mizuho Securities | Analyst unavailable | $192 | $181.68 | -48.9% | May 8, 2026 |
| Barclays | Luke Sergott | $220 | $181.68 | -41.5% | May 8, 2026 |
| Barclays | Luke Sergott | $210 | $178.34 | -44.2% | Apr 14, 2026 |
| RBC Capital | Analyst unavailable | $215 | $178.34 | -42.8% | Apr 14, 2026 |
| Mizuho Securities | Analyst unavailable | $175 | $164.24 | -53.5% | Feb 20, 2026 |
| Robert W. Baird | Eric Coldwell | $193 | $158.18 | -48.7% | Feb 19, 2026 |
| Barclays | Luke Sergott | $200 | $158 | -46.8% | Feb 19, 2026 |
| Robert W. Baird | Analyst unavailable | $231 | $221.69 | -38.6% | Jan 13, 2026 |
| Evercore ISI | Analyst unavailable | $260 | $225.11 | -30.9% | Jan 13, 2026 |
| Robert W. Baird | Eric Coldwell | $224 | $219.49 | -40.4% | Jan 9, 2026 |
| Mizuho Securities | Ann Hynes | $215 | $215.51 | -42.8% | Jan 9, 2026 |
| Mizuho Securities | Analyst unavailable | $200 | $195.98 | -46.8% | Dec 18, 2025 |
| Barclays | Analyst unavailable | $215 | $192.97 | -42.8% | Dec 15, 2025 |
| Morgan Stanley | Kallum Titchmarsh | $185 | $176.09 | -50.8% | Dec 1, 2025 |
| Argus Research | Analyst unavailable | $200 | $166.73 | -46.8% | Nov 17, 2025 |
| Mizuho Securities | Ann Hynes | $174 | $174.95 | -53.7% | Oct 17, 2025 |
| Evercore ISI | Elizabeth Anderson | $200 | $181.18 | -46.8% | Oct 3, 2025 |
| Barclays | Luke Sergott | $195 | $170.48 | -48.2% | Oct 2, 2025 |
| Jefferies | Analyst unavailable | $195 | $157.38 | -48.2% | Sep 9, 2025 |
| Barclays | Luke Sergott | $205 | $193.14 | -45.5% | Oct 15, 2024 |
| Redburn Partners | Jamie Clark | $151 | $192.97 | -59.9% | Oct 14, 2024 |
| Mizuho Securities | Ann Hynes | $210 | $206.44 | -44.2% | Sep 17, 2024 |
| Deutsche Bank | Justin Bowers | $240 | $200.34 | -36.2% | Aug 8, 2024 |
| Robert W. Baird | Eric Coldwell | $239 | $201.85 | -36.5% | Jul 10, 2024 |
| Barclays | Luke Sergott | $230 | $207.35 | -38.8% | Jun 28, 2024 |
| Goldman Sachs | Matthew Sykes | $290 | $216.12 | -22.9% | Jun 6, 2024 |
| Evercore ISI | Elizabeth Anderson | $265 | $230.09 | -29.5% | May 9, 2024 |
| Evercore ISI | Elizabeth Anderson | $300 | $270.95 | -20.2% | Apr 1, 2024 |
| KeyBanc | Donald Hooker | $300 | $257.51 | -20.2% | May 5, 2022 |
| Wells Fargo | Analyst unavailable | $325 | $257.75 | -13.6% | Apr 25, 2022 |
| Jefferies | David Windley | $280 | $273.03 | -25.6% | Apr 25, 2022 |
| Jefferies | David Windley | $464 | $357.95 | +23.4% | Jan 11, 2022 |
| Argus Research | David Toung | $440 | $377.51 | +17.0% | Nov 24, 2021 |
| Cowen & Co. | Daniel Brennan | $465 | $417.45 | +23.6% | Aug 17, 2021 |
| Credit Suisse | Katie Tryhane | $385 | $416.31 | +2.4% | Aug 4, 2021 |
| J.P. Morgan | Tycho Peterson | $390 | $337.99 | +3.7% | May 28, 2021 |
| Guggenheim | Sandy Draper | $369 | $329.52 | -1.9% | May 25, 2021 |
Track every rating change on CRL the moment it posts. Free to start.
Start freeGet the CRL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.